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ABSTRACT
The novel peptide preptin consists of 34 amino acid residues corresponding to Asp 69-Leu102 of proinsulin-like growth factor E-peptide. Preptin has been isolated from pancreatic beta cells, and it
has been found to exhibit both metabolic and mitogenic activities. This makes preptin an attractive
candidate to treat insulin-independent diabetes and osteoporosis. Alanine scanning mutagenesis
was utilized to substitute an alanine for residues Trp27, Arg28, and Gln29 of preptin in order to
ultimately study the structure-activity relationship of these residues to preptin’s metabolic activity.
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I.

Introduction and Background Information
A. Diabetes and Cancer
The United States is experiencing an epidemic of chronic disease. Six in ten Americans

have a chronic disease and four in ten have two or more.1 On a global level, chronic diseases are
the leading cause of death and disability.2 The most prevalent forms include diabetes, cancer, heart
disease, stroke, and chronic respiratory diseases. 2 In 2017, diabetes alone accounted for $327
billion in total healthcare costs, and every year, approximately 1.5 million Americans are
diagnosed with the disease.3 In 2015, diabetes was the seventh leading cause of death in the U.S.
It was written as the cause of death for 79,535 individuals and listed as a contributing cause of
death for an additional 252,806 deaths.3 Individuals with diabetes are at an increased risk for a
spectrum of complications, including hypertension, stroke, gastroparesis, and neuropathy. 4
Diabetes mellitus refers to a group of related metabolic disorders revolving around
deficiency or inefficiency in the insulin signaling system. Type 1 and type 2 diabetes are the most
common forms of diabetes. Type 1 diabetes is an autoimmune disease in which the immune system
destroys the insulin-secreting beta cells in the pancreas. The loss of beta cells inhibits the body’s
ability to secrete insulin; this type of diabetes accounts for 5-10% of diabetes cases. 5 Type 2
diabetes is the more prevalent form and affects the body’s ability to metabolize glucose. In the
early stages of type 2 diabetes, the pancreas often secretes insulin at levels higher than normal in
order to maintain blood glucose levels. However, as the body continues to resist the effects of
insulin, the pancreas loses its ability to secrete insulin properly, leading to type 2 diabetes. 6
In addition to the direct effects of diabetes, there is epidemiological evidence to suggest
that individuals with diabetes have a 20-25% increased risk of cancer, depending on the type,
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compared to non-diabetic individuals.7,8 It is also suggested that mortality in cancer patients
increases significantly if the patient is also diabetic.7 Like diabetes, cancer manifests from irregular
cell signaling. Genetic and epigenetic alterations allow cells to bypass homeostatic mechanisms
that control survival and migration in the body, leading to the overproliferation of cells. 9
Many risk factors coincide for diabetes and cancer including age, sex, weight, physical
activity, nutrition, alcohol, and smoking.7,10 However, the link between these two diseases is not
fully understood. Several hormones that participate in both metabolic and mitogenic pathways
have been identified. The metabolic pathways are key in energy regulation and associated with
diabetes, while the mitogenic pathways are key in cell growth and associated with cancer. Due to
the prevalence of chronic disease worldwide, it is necessary to explore and understand these
hormones, their structures, and their pathways. These hormones include but are not limited to
insulin, insulin-like growth factors (IGF), and the recently discovered preptin.

B. Preptin
Insulin-like growth factors are peptide hormones that function to stimulate growth but also
can decrease the levels of blood glucose.11 The two types of insulin-like growth factors are IGF-I
and IGF-II. The translation product of the insulin-like growth factor II gene is pre-pro-IGF-II,
which is 180 amino acids long and organized into five domains (A through E). Pre-pro-IGF-II
contains a 24 amino acid long N-terminal signal peptide, a 67 amino acid long mature protein
(IGF-II), and an 89 amino acid long C-terminal E domain.12,13 Proteolytic cleavage, the process of
breaking peptide bonds between amino acid residues in protein, of the signal peptide forms proIGF-II. Subsequent proteolysis of pro-IGF-II results in the cleavage of mature IGF-II protein and
the E-domain.13 Preptin is the 34 amino acid peptide corresponding to Asp 69-Leu102 of pro-IGF-II
E-peptide.14
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Figure 1. Schematic representation of the IGF-II gene (red), which is translated to pre-pro-IGF-II
(orange). Pre-pro-IGF is proteolytically cleaved into pro-IGF-II (green). Subsequent proteolysis
yields mature IGF-II (purple) and the E-domain. Preptin (blue) is the 34 amino acid peptide of the
E-domain.13
In 2001, preptin was isolated from βTC6-F7 cells in rats by Buchanan et al., and its
sequence has been greatly conserved throughout evolution in both humans and mice (Figure 3). 14,15
Human and mouse preptin are 79.41% similar, human and rat preptin are 75.53% similar, and rat
and mouse preptin are 94.12% similar.15

Figure 2. Preptin cleavage product of rat pro-insulin-like growth factor II between residues 68 and
103.
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Comparative amino acid sequences among human, rat, and mouse preptin
Human

R68-DVSTPPTVLPDNFPRYPVGKFFQYDTWKQSTQRL-RR 104

Rat

R68-DVSTSQAVLPDDFPRYPVGKFFKFDTWRQSAGRL-RR104

Mouse

R68-DVSTSQAVLPDDFPRYPVGKFFQYDTWRQSAGRL-RR104

Figure 3. Preptin sequence among humans, rats, and mice with differences indicated in bold.
The main sources of preptin are cells of the kidney, liver, pancreas, salivary gland, and
mammary tissue.15 The physiological and biochemical functions of preptin include cell
differentiation, cell proliferation, bone density regulation, metabolic adaptation, and homeostasis
regulation.15 Its ability to affect cell differentiation and proliferation relate to its mitogenic
activity in bone. Preptin also affects homeostasis regulation as it pertains to glucose metabolism.
Preptin and insulin are co-secreted from pancreatic beta cells in response to glucose, and they
help shuttle glucose into the muscles and tissues for energy use. Preptin behaves in a
concentration dependent manner, like insulin.14,16 If more glucose is present, there will be a
greater secretion of both preptin and insulin to balance the levels of glucose in the blood within
the narrow range required for homeostasis.
Preptin’s metabolic properties can be seen with its similar behavior to the FDA-approved
drug glibenclamide. Glibenclamide belongs to the widely-used class of drugs known as
sulfonylureas, and it is used as a treatment for type 2 diabetes. Individuals with type 2 diabetes
have difficulty metabolizing glucose because their bodies begin to resist the effects of insulin, and
the pancreas loses its ability to secrete insulin properly. Glibenclamide helps with this by
stimulating pancreatic beta cells to secrete insulin, and it can do this in the presence or absence of
a glucose challenge by “blocking ATP-sensitive potassium channels in pancreatic beta
cells.”15,16,18 These ATP-sensitive potassium channels are also shared by the cardiovascular
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system. During ischemia, the restriction of blood supply to the myocardial tissue, these channels
open because the levels of ATP in the cytosol decrease.18 There is a protective mechanism for the
cardiovascular system called “ischemic preconditioning,” which utilizes a brief period of ischemia,
and it aims to protect against prolonged ischemic injury to the heart. 19 Sulfonylureas, such as
glibenclamide and tolbutamide, have been found to block the opening of the ATP-sensitive
potassium channels in myocardial tissue and vascular smooth muscle cells, which could lead to
interference of the cardioprotective mechanism of ischemic preconditioning. 20 Furthermore,
because glibenclamide can stimulate insulin secretion without the presence of glucose, it can lead
to severe hypoglycemia, which is a state of low blood glucose that can be characterized by seizures
and loss of consciousness.18,21 This hypoglycemic state is the most likely culprit in the adverse
consequences of glibenclamide and other sulfonylureas on the cardiovascular system. 18 The risks
of glibenclamide, along with other diabetic drugs, drives the search for other potential treatments,
one of which is preptin. In rats, preptin stimulates insulin secretion in similar concentrations to
glibenclamide in vitro, although preptin’s pathway is not fully understood.15 Unlike glibenclamide,
however, preptin is self-regulating, meaning that when glucose levels are not elevated, the body’s
natural regulatory system resists preptin’s action and prevents hypoglycemia.
In addition to preptin’s potential as a treatment for diabetes, it is also being considered as
a treatment for osteoporosis because of its osteogenic nature in vivo and in vitro.22 Osteoporosis is
characterized by an imbalance in bone metabolism, the cycle of growth and resorption of bone
guided by osteoblasts, osteoclasts, hormonal and regulatory signals. 23 If resorption of bone is
greater than the growth of bone, osteoporosis can develop.23 The current therapies for preventing
osteoporosis target bone resorption but have limited ability to improve bone mass. 22 This makes
preptin a good candidate for treatment of osteoporosis, as it stimulates bone formation and can
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positively impact bone mass.22 Similar to insulin and other products of the pancreatic beta cell,
preptin encourages bone anabolism via the proliferation and survival of osteoblasts. 22 However,
preptin does not impact osteoclast activity and the removal of bone tissue. 22. Homeostasis of bone
is mediated by both osteoblast and osteoclast activity, so preptin’s ability to affect only the boneforming side of this equation could lead to uncontrolled cell growth, manifesting diagnostically as
cancer. Preptin is also expressed alongside insulin-like growth factor II, as they are both cleavage
products of the pro-insulin-like growth factor II. Upon binding of IGF-II to its receptor, mitogenic
(cell growth) pathways are initiated.24 For preptin to become a useful drug, its metabolic and
osteogenic activities must be separated to avoid a cancerous state.
Kowalczyk et al. previously established that the first 16 amino acid residues of preptin’s
sequence stimulated bone growth and increased the survival of osteoblasts in rats. 25 This fragment
was not active in the pancreas nor did it affect glucose metabolism. 25 However, because this
peptide fragment was still relatively large for a therapeutic, this group performed truncations to
determine the smallest fragment that performed the same function of bone anabolism. 25 A short
eight amino acid fragment of preptin (1-8) was identified as critical to the proliferation of
osteoblasts and the enhancement of bone formation in rats. 25 The work by Kowalczyk et al. was
done to elucidate preptin’s mitogenic activity in bone, but no such work has been done to identify
fragments necessary for its metabolic activity.
Because research has not been done to investigate preptin’s metabolic activity, this work
aimed to address that disparity. A review of the C-terminal end of the rat preptin sequence revealed
a three-residue region with interesting properties. Residues Trp27 (tryptophan), Arg28 (arginine), and
Gln29 (glutamine) each have long side-chain when compared to other amino acids (Figure 4). The

proximity of these long side-chains coupled with their properties suggests that this region of the
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peptide may interact with the target receptor, which is currently unknown. One chemical property
exhibited tryptophan is aromaticity. Aromatic rings possess stability from the pi-electrons above
and below the plane of the ring; these aromatic rings have been demonstrated to participate in pistacking with other side chains in protein-protein interactions. 26 In addition, arginine exhibits the
physical property of electric charge. Arginine is a positively charged amino acid, and repetitive
arginine residues have been shown to be a key recognition site in protein-protein interactions.
Taken together, this region presented a good place to start investigating the structure-activityrelationship of these three residues of preptin. The goal of this work was to analyze amino acid
residues Trp27, Arg28, and Gln29 of rat preptin using alanine scanning mutagenesis to better
understand the structure-activity relationship of these residues to the peptide.

Figure 4. Amino acid residues Trp27, Arg28, and Gln29 of preptin’s 34 amino acid long sequence.
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C. Alanine Scanning Mutagenesis
Site-directed mutagenesis is used to create specific changes to double-stranded plasmid
DNA. This is often done to screen for mutations, introduce or remove endonuclease sites, or
change the sequence of a gene product.27 Alanine-scanning mutagenesis is the commonly used
form of site-directed mutagenesis, and it alters the DNA sequence to encode an alanine in place of
the naturally occurring amino acid of interest.28 Substitution of an alanine into the polypeptide
gene product does not alter the “main-chain conformation” like glycine or proline and keeps the
native protein intact.28 It also does not inflict electrostatic or steric effects because it is uncharged
and its side chain is a simple methyl group.28 However, alanine substitution does alter the sidechain profile of the polypeptide by essentially removing the native side chain. If an altered
polypeptide shows reduced activity when the native side-chain is removed, that is an indication
that the native side-chain participates in the active or binding site of the polypeptide.

D. Cloning
Cloning is a technique of making identical copies of a piece of DNA. A cloning vector is
a piece of DNA into which a desired DNA fragment can be inserted. In traditional cloning methods,
vectors are based on bacterial plasmids; these plasmids have DNA that is circular and doublestranded, and they replicate independently of genomic DNA.29 Cloning vectors that are based on
plasmids have various elements including an origin of replication, restriction enzyme sites or
multiple cloning site (MCS), and markers that help determine successful uptake of the desired
vector.29
There are four steps to the traditional cloning procedure: use restriction enzymes to select
a desired gene from an organism, insert the desired gene into a vector, transform the vector into
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bacteria, and isolate the vector DNA for purification.30 Because DNA is selected from one
organism and transplanted into a vector, cloning can also be referred to as recombinant DNA
technology. It can be used to determine the function of a gene, determine how mutations affect the
function of a gene, and make large quantities of protein encoded by the gene. 30

E. Inverse Polymerase Chain Reaction Mutagenesis
Polymerase chain reaction (PCR) cloning differs from the traditional cloning procedure
because the vector and the DNA fragment of interest can be amplified and ligated together without
restriction enzymes.31 The polymerase chain reaction also allows for the exponential amplification
of small quantities of DNA. The process involves three steps: initial denaturation, thermocycling,
and final extension of DNA. During the initial denaturation, the double-stranded DNA is subjected
to a high temperature, typically between 94 and 98C, and incubated for a longer time to guarantee
that the double-stranded DNA is fully separated prior to the thermocycling. 32,33 The time must be
long enough to ensure the denaturation of the strands for priming but not long enough to damage
the DNA.30 The high temperature disrupts the hydrogen bonds between nucleotide bases of the
double-stranded DNA to separate it into single strands.33,34 Initial denaturation helps to ensure that
optimal amplification occurs during the first amplification cycle. Thermocycling entails the
repetition of another denaturation step along with annealing and extension and is typically carried
out for 25 to 35 cycles, although this is determined by the amount of DNA to be amplified and the
desired yield.33,35 PCR primers are short segments of single-stranded DNA that bind to their
complementary sequences on single-stranded DNA during the annealing step. The primertemplate heteroduplex forms, acting as an initiation complex for the DNA polymerase to perform
extension.33,34 Extension is the last step in thermocycling, and this is when DNA Taq polymerase,
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the most commonly used polymerase in PCR, extends the primer sequences at the 3’ end to the
end of the amplicon.33 This step is important to amplification because of its specificity:
amplification will only occur to molecules with sequences complementary to the primers. 31 The
ideal temperature for extension is 72C, as that is the optimal temperature for the DNA Taq
polymerase.34 The final extension step occurs after the last cycle and DNA polymerase extends the
primer sequences.33 Its duration depends on the length of the amplicon and must be long enough
to ensure complete polymerization and adequate yield of the DNA. 34
The traditional PCR technique used for site-directed mutagenesis utilizes primers that flank
the target gene or fragment that is to be copied. The primers are designed with the desired mutation,
and during the PCR, the mutation is incorporated into the gene or fragment. However, this method
is limited in amplification to the sequence between two inward-pointing primers, and extension
cannot exceed the segments upstream and downstream from the region of interest. 36,37 This method
also requires additional steps to ligate the amplified DNA sequence into a linear plasmid.
On the other hand, inverse PCR mutagenesis is a faster and more efficient method of
mutagenesis when compared to the traditional mutagenesis protocol. Inverse PCR mutagenesis
differs because it uses back-to-back non-overlapping primers (Figure 5) to amplify the entire
plasmid instead of just a target segment. The forward primer has the desired mutation, and the
reverse primer allows them to anneal back-to-back. The segment of DNA containing the mutation
and the vector itself can be amplified and ligated together without restriction endonucleases. 31
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Figure 5. Back-to-back primers are indicated by the arrows, and they are efficient at incorporating
substitutions, deletions, and insertions into double-stranded plasmid DNA. 38
Inverse PCR mutagenesis produces linear plasmid products that require circularization.
This is accomplished by incubation with the enzymes kinase and ligase. Kinase phosphorylates
the 5’ ends of the linear PCR products so they can be circularized by the enzyme ligase. Ligase
recognizes the phosphorylated 5’ ends of the linear double-stranded PCR products and creates a
new phosphodiester bond with the free 3’ ends. This reaction completes the plasmid syntheses
process. However, to prevent the introduction of the unmutated template plasmid into the cells, it
is removed by DpnI, an enzyme that digests methylated DNA.38 The template plasmid was isolated
from a bacterial source, so it is naturally methylated. The methylated nucleotides are recognition
sites for DpnI, and DpnI cleaves the double-stranded plasmid DNA. Since the PCR products are
not methylated, the nucleotides are not recognized by DpnI, and the DNA ise not cut. Once the
template plasmid has been digested, the mutated circular plasmids can be introduced to E.coli
cells.38 This is known as transformation, and it is the process by which exogenous DNA is acquired
by an organism. The entirety of the cloning procedure can be seen in Figure 6.
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Figure 6. Basic schematic diagram of inverse PCR mutagenesis, KLD reaction, and
transformation. The forward primer with desired mutation is indicated by the red arrow while the
reverse primer is indicated by the blue arrow. Upon completion of amplification of the linearized
plasmid with the desired mutation, the KLD reaction is performed to circularize the DNA and
eliminate the template plasmid.
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F. Primer Design
Primers are short sequences of nucleic acids, either DNA or RNA, that are complementary
to the template DNA sequence. DNA replication cannot occur without primers. DNA polymerase
can only add nucleotides to a free 3’ hydroxyl end, which is not available on a single-strand of
template DNA. Primers base-pair to single-stranded template DNA and offer a free 3’ hydroxyl
end for the polymerase to add an incoming nucleotide. During the polymerase chain reaction,
primers allow for the association of DNA polymerase after denaturation of double-stranded DNA
and before elongation of the sequence.
Primer design is crucial to the PCR process, and it helps balance the specificity and
efficiency of DNA amplification.39 The specificity refers to the likelihood that a mispriming event
occurs while efficiency refers to the ability of the primer pair to amplify the PCR product to the
theoretical maximum, which is a twofold increase of the PCR product per cycle. 39 The length of
the primer and the annealing temperature of the PCR reaction are two variables that control the
specificity, and the typical length for most PCR amplification is 18 to 30 bases. 39,40 A shorter
primer could lead to the formation of nonspecific and undesirable PCR products, and a longer
primer could result in a smaller quantity of primed templates during annealing. 39,40 In the latter
case, this small inefficiency would augment at each annealing step during thermocycling and there
would be a noticeable reduction in the amplified product. Primers of the appropriate length are
also sequence-specific if the annealing temperature is within a few degrees of the melting
temperature (Tm) of the primer.39 The primer sequence is another important feature in primer
design, especially the 3’-end.40 The 3’-end is critical because its composition regulates the
specificity and sensitivity of the PCR reaction. There should not be 3 or more guanosine or cytosine
bases on this end of the primer, as this could stabilize nonspecific annealing onto the template. 40
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A thymidine on the 3’-end would also affect specificity because this nucleotide is more susceptible
to mispriming.40 Design of the 3’-end primer should include a restriction site, stop codon, and
overlap with the strand opposite the 3’-end of the specific gene. 40 The 5’-end of the primer is not
as important for annealing, but there are several elements that it must contain: a restriction site, 5’extension to the site, start codon, and overlap with the specific gene target. 40
For inverse PCR mutagenesis, back-to-back non-overlapping primers are utilized. These
primers can be used for substitutions, deletions, small and large insertions. Substitutions are made
by incorporating the desired nucleotide substitutions in the forward primer, leaving at least 10
nucleotide bases on the 3’ end. The reverse primer must be designed so that the 5’ ends of both
primers anneal back-to-back (Figure 7).

Figure 7. Primer design for substitution with the forward primer (black), reverse primer (red), and
desired nucleotide change (*).38
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G. Gel Electrophoresis
Agarose gel electrophoresis is a method for separating, identifying, and purifying DNA
fragments and can also be used to separate RNA and proteins. Gel electrophoresis utilizes an
electric field to move DNA, which is negatively charged, through an agarose gel towards a positive
electrode.41 It has three main steps with the first being the preparation of the gel with a
concentration of agarose appropriate for the size of the DNA.42 The second step is loading the
DNA samples containing dye into sample wells alongside a molecular weight ladder and running
them at a voltage using a voltage source and electrodes.41,42 A molecular weight ladder is a
collection of fragments of DNA of known lengths, and this ladder is necessary to estimate the
length of the simultaneously run samples.41 The last stage involves either the staining of the gel or
illumination of the gel containing ethidium bromide with UV light. 42

Figure 8. Schematic diagram of gel electrophoresis illustrating the loading of the wells, the
movement of DNA and separation into bands, and the UV illumination of the bands in the gel
containing ethidium bromide.43
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II.

Methods and Materials
A. Plasmid Design
1.
2.
3.
4.
5.
6.

Rat Preptin Ala21 Gene
His6 Affinity Tag
GFP fusion protein
TEV Protease recognition site
Ampicillin Selection Marker
LAC Operon Inducible Promoter

A custom synthetic plasmid (pD444-SR:His6-GFP-TEV-Preptin Ala 21, Figure 9) was
purchased from ATUM. The plasmid was designed to encode for a rat-preptin analog with a His 6green fluorescent protein (GFP) tag. The preptin analog contained an alanine mutation at residue
21, previously a phenylalanine, to prolong the half-life of the hormone in vivo.44 Our lab lacks
access to a preparative HPLC or UV detector capable of purifying our fusion protein. Therefore,
the gene for the GFP protein was inserted on the 5’ end of the preptin gene. GFP was isolated from
the Aequorea Victoria jellyfish, and it produces a strong fluorescence emission peak at 509 nm
and an excitation peak at 395 nm. This allows the fusion protein to be tracked during purification
using an affordable UV penlight. After the fusion protein has been isolated, the His 6-GFP tag can
be removed by incubation with the tobacco etch virus (TEV) protease. The TEV protease is highly
site-specific, and the gene for the His6-GFP fusion tag includes the recognition sequence for
cleavage on its C-terminal end.
The plasmid also contains a gene for ampicillin resistance. This was useful during the
transformation of the mutated plasmids into E. coli cells, as only the cells that were successful at
incorporating the plasmid survived and grew while those that did not were killed by the ampicillin
on the plates.
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In E. coli, the lac operon, which is the orange portion of the plasmid map, codes for
enzymes involved in the metabolism of lactose. The lac operon is efficiently expressed when
lactose is present and glucose is not, and transcription of the operon is regulated by the lac
repressor and the catabolite activator protein (CAP). Isopropyl-β-D-thiogalactopyranoside (IPTG)
is a molecular mimic of allolactose (lactose metabolite) and can be used to bind and inhibit the lac
repressor by changing its conformational state. This allows for the expression of the lac operon.
IPTG is not metabolized by E. coli cells, which ensures that the concentration of IPTG remains
constant and continues to induce the expression of the lac operon. Thus, IPTG allows for the
transcription of the DNA by RNA polymerase and subsequent translation into protein. This gives
a method for enhancing protein expression.

Figure 9. Plasmid map of pD444-SR:His6-GFP-TEV-Preptin Ala 21.
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B. Primer Design
NEBasechanger was used to design the forward and reverse primers for the three mutations
and calculate the annealing temperatures. Both the forward and reverse primers were necessary to
perform the desired alanine substitutions using the NEB Q5 Site-Directed Mutagenesis Kit. The
base pairs for the forward primers and the mutations are located in Table 1 and were obtained from
the plasmid sequence in the Appendix. Table 2 features the sequences that were sent to New
England BioLabs to create the custom primers along with the melting and annealing temperatures
specific to the primers.

Table 1. Base pair sequences for the forward primers and mutations for W27A, R28A, and Q29A.
Corresponding Base Pair Sequence
W27A Forward Primer

2349-2371

W27A Mutation

2359-2361

R28A Forward Primer

2352-2374

R28A Mutation

2362-2364

Q29A Forward Primer

2355-2377

Q29A Mutation

2365-2367
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Table 2. Sequences, melting temperatures (Tm), and annealing temperatures (Ta) of the forward
and reverse primers with the mutation to alanine in red.
Primer

Sequence

Tm

Ta

W27A Forward

GTTCGACACGgcaCGTCAGAGCG

61°C

62°C

W27A Reverse

TTAAACGCTTTGCCCACC

64 °C

62°C

R28A Forward

CGACACGTGGgcaCAGAGCGCGG

63°C

62°C

R28A Reverse

AACTTAAACGCTTTGCCC

61°C

62°C

Q29A Forward

CACGTGGCGTgcaAGCGCGGGTC

62°C

58°C

Q29A Reverse

TCGAACTTAAACGCTTTG

57°C

58°C

Figure 10. Design of the W27A primer with the forward primer (red), reverse primer (blue), and
the alanine mutation (grey).

C. Selection
One of the most common ways to culture bacteria is using Luria broth (LB) agar plates
(Figure 11). The LB is a nutrient-rich media, and agar is added to the LB to create a gel that is
suitable for bacterial growth; bacteria cannot digest agar but receives nutrients from the LB. During
this study, ampicillin was added to the gel to grow up the cells that successfully incorporated the
specific, antibiotic-resistant plasmid. Luria broth-ampicillin plates were prepared by spreading 40
µL of 500x ampicillin in 100 µL of distilled water onto 20 mL LB-agar plates.
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Figure 11. Luria broth-ampicillin plates with visible colonies.

D. Mutagenesis
The commercially available Q5® Site-Directed Mutagenesis Kit (New England BioLabs,
Inc) was used to perform the cloning procedure. The overview of this process is seen in Figure 12.

Figure 12. Overview of the NEB Q5 Site-Directed Mutagenesis Kit. 21
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An important note for this kit is that it utilizes a Q5 high-fidelity polymerase instead of Taq
polymerase. The protocol provided by the manufacturer was followed with minimal changes. The
first step of the mutagenesis protocol was exponential amplification. The reagents in Table 3 were
assembled in a PCR tube, mixed completely, and transferred to a Eppendorf Mastercycler Personal
thermocyler (PCR reaction conditions are in Table 4).

Table 3. Reagents for exponential amplification.
25.1 μL RXN Final Concentration
Q5 Hot Start High-Fidelity 2X Master Mix

12.5 μL

1X

10 μM Forward Primer

1.3 μL

0.5 μM

10 μM Reverse Primer

1.3 μL

0.5 μM

Template DNA (1-25 ng/μL)

1.0 μL

1-25 ng

Nuclease-free water

9.0 μL

Table 4. Conditions for thermocycling.
Steps

Temperature (C)

Time

Initial Denaturation

98

30 s

25 Cycles:

98

10 s

62

30 s

72

30 s/bp = 80

Final Extension

72

2 mins

Hold

4
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The second step was the simultaneous phosphorylation and ligation of the linear PCR
products with concurrent digestion of the template plasmid. The kinase, ligase, and digestion
enzymes (Table 5) were added to the PCR tube, mixed thoroughly with a pipette, and incubated at
room temperature for five minutes.
Table 5. Reagents for KLD reaction.
Volume Final Concentration
PCR Product

1 μL

2X KLD Reaction Buffer

5 μL

1X

10X KLD Enzyme Mix

1 μL

1X

Nuclease-free water

3 μL

After the KLD reaction, the mutated circular plasmids were used for transformation of
competent E. coli cells. NEB 5-alpha competent E. coli cells (50 µL, included with the kit) were
thawed, and 5 µL of the KLD mixture from the second step was added to the cells. The tube was
flicked to mix. Flicking ensured that the cells were not damaged, which could occur if they were
vortexed. The mixture was placed on ice for 30 minutes, heat shocked at 42°C for 30 seconds, and
placed back on ice for 5 minutes. The heat shock encouraged the bacterial cells to take up the
mutated plasmid. Then, 950 µL of room temperature SOC broth (Super Optimal Broth with 20
mM glucose) was pipetted into the mixture and incubated at 37 °C for 60 minutes in a Thermo
Scientific MaxQ 400 Incubator while shaking at 250 rpm. The cells were then mixed via flicking
and inverting the tube, and 75 µL of each transformation reaction was spread onto LB-ampicillin
plates and incubated overnight at 37°C. Overnight, the bacterial that did not incorporate the
ampicillin-resistant plasmid died off. The bacteria that successfully incorporated the plasmid

23

survived and reproduced. Each surviving bacterium gave rise to a colony of identical, plasmidcontaining bacteria.

E. Overnight Culture for Plasmid Isolation
The morning following the transformation of W27A, R28A, and Q29A analogs, the LBampicillin plates were observed for growth. One colony was picked from each plate and used to
inoculate 4 mL LB cultures with 8 mL 500X ampicillin. The cultures were then returned to the
Thermo Scientific MaxO 400 Incubator for 16 hours at 37 °C while shaking at 250 rpm. To avoid
having to perform the mutagenesis every time plasmid is required, glycerol stock solutions were
prepared by mixing 500 µL of the cell culture with 500 µL of 50% glycerol. The glycerol stock
was then stored at -80°C.

F. Plasmid Isolation
An Invitrogen PureLink Quick Plasmid Miniprep Kit was used to isolate the plasmid DNA
from E.coli cells via cell lysis. The first step in the plasmid isolation protocol was to centrifuge 3.5
mL of the 16-hour overnight LB culture and remove the medium. Resuspension buffer with RNase
A (250 µL) was added to the pellet of cells and resuspended until homogenous. Lysis buffer (250
µL) was added and mixed gently by inversion of the tube until homogenous. This was incubated
at room temperature for five minutes. Precipitation buffer (350 µL) was added and mixed by
inversion until homogenous. The lysate was centrifuged 13,000 x g for ten minutes. The
supernatant from the precipitation step was loaded onto a spin column in a 2 mL wash tube, which
was then centrifuged at 12,000 x g for one minute. The flow through was discarded, and the column
was placed back into the wash tube. An optional wash step was performed in which 500 µL wash
buffer (W10) with ethanol was added to the column and incubated for one minute at room
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temperature. Wash buffer (W9) with ethanol (700 µL) was added to the column and centrifuged at
12,000 x g for one minute. The flow-through was discarded, and the column was placed back into
the wash tube. The column was centrifuged again at 12,000 x g for one minute and the flowthrough discarded. The spin column was then placed in a 1.5 mL elution tube, and 75 µL of
nuclease free water was added to the center of the column. The column was incubated for one
minute at room temperature. The column was centrifuged at 12000 x g for two minutes. This
resulted in the purified plasmid DNA being contained in the elution tube.

G. Gel Electrophoresis
A 1% agarose gel was prepared by dissolving 0.50 g agarose in 100 mL of Tris Acetate
EDTA (TAE) buffer (pH 8.3), which was prepared by mixing 300 mL of 1X TAE buffer with 7.5
µL of ethidium bromide (visualizing agent). Plasmid samples for gel electrophoresis were prepared
by adding 5 µL DNA, 4.2 µL NEB purple loading dye, and 15.8 µL nuclease free water in a
microcentrifuge tube. Portions of the plasmid samples (20 µL) were pipetted into separate lanes of
the agarose gel and run at 110 V and room temperature.

H. DNA Sequencing
Samples of the mutated plasmids of W27A, R28A, and Q29A were sent to MCLabs in
California for analysis. Sanger sequencing was used to confirm the presence or absence of the
alanine mutations.
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III.

Results and Discussion
A. Rationale

Preptin exhibits both metabolic and mitogenic properties, so it has the potentiality of being
used as a treatment for types 2 diabetes and osteoporosis. This is especially important due to the
adverse effects seen with glibenclamide, one of the most common drugs for type 2 diabetes.
Glibenclamide and preptin behave similarly in regard to stimulating insulin secretion. However,
the pathway by which preptin accomplishes this is unknown. This work was performed to study
the structure-activity relationship of the three chosen amino acid residues in order to ultimately
assess the effect of the mutations on the metabolic activity of preptin. Amino acid residues Trp27,
Arg28, and Gln29 of rat preptin were chosen for their properties, such as aromaticity and charge, and

their potential to interact with the unknown preptin receptor.

B. Results
Various factors came into conflict with this research. The first problem occurred during
our initial efforts at cloning, which presented itself during transformation of the cells. We were
having trouble growing up any successful colonies, so we knew that some step of the cloning
procedure was not working properly. To determine which step, the original plasmid, PCR product,
and KLD product for one of the analogs were analyzed in an agarose gel. The band for the original
plasmid was strong, but the band for the PCR product was barely visible. We hypothesized that
this faintness was the presence of the original plasmid that did not mutate, and this meant that the
PCR was not working. The KLD did not have any bands, which further supported this hypothesis.
The NEB Q5 Mutagenesis kit itself was tested to see if that was the problem, and the control
plasmid from the kit, PCR product, and KLD product were analyzed in an agarose gel, and the
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lanes displayed that the kit was not the problem. We contacted New England BioLabs and were
advised to increase the annealing temperature, as the Q5 high-fidelity polymerase requires higher
temperatures. The increase in annealing temperature proved successful.
The second problem we encountered stemmed from the construction being done in LeNoir
Hall and our lab. Transformation of the NEB 5-alpha E. coli cells with our mutated plasmid and
subsequent purification was unsuccessful. Analysis of gel electrophoresis concluded that no
plasmid was present because of the absence of bands. From increasing the annealing temperatures
and ensuring that cloning was successful, we knew that there had to be another cause and tested
the ampicillin. To do this, untransformed cells (not ampicillin-resistant) were streaked onto an LBampicillin plate, transformed cells (ampicillin-resistant) were streaked onto an LB-ampicillin
plate, and untransformed cells were streaked onto a kanamycin (a different antibiotic) plate.
Ideally, the E. coli cells that incorporated the ampicillin-resistant plasmid should have grown up
on the LB-ampicillin plate in small colonies. However, both the plate with the untransformed cells
and transformed cells on LB-ampicillin plates had plaque growth. The kanamycin plate had no
growth at all, and this was to be expected since the untransformed cells were not ampicillin- or
kanamycin-resistant. We hypothesize that the move to the new lab resulted in our ampicillin being
left at improper temperatures for storage, and degradation occurred. We obtained a new ampicillin
stock to use during transformation in the plates and the cell cultures.
After resolving the problems with cloning and with degraded ampicillin, purification of the
plasmids containing mutations encoding for W27A, R28A, and Q29A from the transformed cells
was confirmed, seen in Figure 13.
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Figure 13. Gel electrophoresis for mutations W27A (Lane 4), R28A (Lane 5), and Q29A (Lane
6).
Figures 14, 15, and 16 display the DNA sequencing results of the mutated plasmids. The
mutation at residue 27 was inconclusive, as the sequencing revealed a valine instead of the desired
alanine. Further inspection of the residues earlier in the sequence (residues 24-26) revealed
disparities from the known sequence for rat preptin. On the other hand, the correct mutations were
obtained for residues 28 and 29, with only a couple of residues at the beginning of the preptin
sequence different in the latter.

28

Figure 14. Sequencing results for the unsuccessful mutation of the GFP-Preptin Ala27 gene
(highlighted in yellow).

Figure 15. Sequencing results for the successful mutation of the GFP-Preptin Ala28 gene
(highlighted in yellow).
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Figure 16. Sequencing results for the successful mutation of the GFP-Preptin Ala29 gene
(highlighted in yellow).
There are various factors that affect the quality of sequencing results. For Sanger
sequencing, which MCLabs used for our preptin analogs, deoxynucleotides (dNTPs) normally
found in DNA are used alongside dideoxynucleotides (ddNTPs) . These ddNTPs have a hydrogen
on the 3’ carbon instead of the hydroxyl group that is found on dNTPs, and because ddNTPs lack
the hydroxyl group, the addition of further dNTPs cannot occur. 45 This results in copious fragments
of various lengths, which are reacted with the four ddNTPs. These ddNTPs are labeled with dye,
and the wavelengths that cause the fragments to fluorescence are accumulated into a
chromatogram.45 The colored peaks in the chromatogram refer to the nucleotides at those positions,
and the codons reflect the amino acids. Errors during this process can be attributed to the absence
of a priming site, degraded primer, insufficient amount of DNA template, residual primers, and
much more.45 However, error from the sequencing protocol seems unlikely, as two of the three
mutations resulted in the correct alanine mutation. Error most likely occurred during the sitedirected mutagenesis, resulting in the plasmid not incorporating the desired alanine mutation.
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C. Future Work
The first issue that will need to be addressed with the continuation of this work is obtaining
a successful mutation of the 27th residue. After that, the main objective of the future work would
be to test the metabolic activity of the preptin analogs using an enzyme-linked immunosorbent
assay (ELISA). The ELISA technique would allow us to quantify the ability of the preptin analogs
to enhance insulin secretion. Prior to this, however, large-scale production and purification of the
analogs must be performed. This will be accomplished by first transforming BL21 cells, which are
better than the NEB 5-alpha cells for protein expression, with the mutated plasmids. Isopropyl-βD-thiogalactopyranoside (IPTG) will be used to induce the cell cultures. IPTG mimics the lactose
metabolite, allolactose, and as stated earlier, it allows for the expression of the lac operon.
Expression of the lac operon leads to the transcription of the DNA and the translation to the preptin
protein. To optimize the expression of preptin, different concentrations of IPTG will need to be
tested to determine the concentration at which the most protein is expressed. After the IPTG
treatment, sonication will be used to disrupt the cell membranes of the bacterial cells and extract
the DNA, RNA, and protein. Nickel affinity chromatography is used to separate the desired
proteins, which have a His6 affinity tag, from the native bacterial proteins that are present. The
nickel columns utilize immobilized metal-affinity chromatography, and the immobilized nickel
resin most likely to be used is nickel-nitrilotriacetic acid (Ni-NTA).46 The NTA is a tetradentate
chelating ligand, and it binds the Ni2+ ions via four coordination sites, leaving two coordination
sites available to interact with the His6 residues of the preptin analogs.47 Thus, proteins with the
His6 tag will have a high affinity for the nickel and become immobilized on the resin, and other
proteins will bind with low affinity or will not bind at all. 47 Immobilized proteins can be washed
through the column using increasing concentrations of imidazole. Size exclusion columns must be
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used in addition to Ni-NTA because of the imidazole and other salts that are introduced during the
separation of the desired protein from native bacterial protein. To assess the purity and yield of the
protein, SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) can be used.
SDS-PAGE separates proteins based on charge and molecular weight. SDS is an anionic detergent
that breaks hydrogen and hydrophobic bonds in proteins while also binding to proteins and
covering their intrinsic charges.48 The only determining factor for the migration of protein through
the gel is the molecular weight, and since the protein is uniformly negatively charged due to SDS,
the protein will migrate towards the positive electrode.49 Proteins with a greater molecular weight
take longer to migrate through the gel while proteins with a smaller molecular weight move more
quickly through the gel. If the sample being tested is pure and contains one protein, the gel will
display one single band representative of the protein; if there are multiple proteins, there will be
multiple bands. Once purity and the molecular weight of preptin have been confirmed, the ELISA
assay can be done to assess the metabolic activity of the preptin analogs, which will be useful in
determining the residues that are vital to the function of the peptide.
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V.

Appendix
A. Plasmid Map and Sequence for pD444-SR:His6-GFP-TEV-Preptin Ala21

Plasmid Map pD444SR:215127
Only single and double cutters are shown in the map.
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Feature Map
Name

Start

Insert: 215127

End

Direction

1522

2385

Forward

Ori_pUC

1

673

Forward

Term_rpoC

918

1037

Forward

Term_bla

1038

1342

Forward

LacO1

1355

1375

Forward

1355

1472

Forward

lacO

1443

1472

Forward

5'UTR_T7_10A

1473

1507

Forward

strong RBS

1510

1521

Forward

2637

2754

Forward

2765

3625

Forward

P_lacI

3626

3707

Forward

lacI

3708

4790

Forward

P_T5_Inducible

P_Amp
Ampicillin-r

Restriction Map
Name

Sequence

5' Cut Positions

AccI

GTMKAC

2287

AclI

AACGTT

1991, 2950, 3323, 3720

AfeI

AGCGCT

1457, 3501

AlwNI

CAGNNNCTG

262

ApaI

GGGCCC

915, 4269

ApaLI

GTGCAC

357, 2880, 4038

AscI

GGCGCGCC

3629

AseI

ATTAAT

3377, 4743

AvaI

CYCGRG

908, 2418

BclI
BglI

TGATCA
GCCNNNNNGGC

4072
919, 3434

BlpI

GCTNAGC

2164

BspEI

TCCGGA

1767, 3461

BspHI

TCATGA

1398, 2712, 4792

BsrBI

CCGCTC

742, 1363(C), 1424(C), 2710

BsrDI

GCAATG

4105(C), 4471

BsrGI

TGTACA

2252

BssHII

GCGCGC

2159, 3629, 4469, 4822
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Name

Sequence

BstEII
BstXI

GGTNACC
CCANNNNNNTGG

5' Cut Positions
4239
3860, 3989, 4112

BtsI

GCAGTG

3133, 3153(C), 4423(C), 4791

EcoRI

GAATTC

2209

EcoRV

GATATC

1255, 4508

HincII

GTYRAC

1273, 2389, 4564

HpaI

GTTAAC

4564

KasI

GGCGCC

1032, 4697

MluI

ACGCGT

4058

MscI

TGGCCA

NarI

GGCGCC

NcoI

CCATGG

1711

NruI

TCGCGA

2627

NsiI

ATGCAT

1526

PciI

ACATGT

PmlI

CACGTG

1546
1033, 4698

671, 1267
2357

PshAI

GACNNNNGTC

1723

PspOMI

GGGCCC

911, 4265

PvuI

CGATCG

2108, 3183

PvuII

CAGCTG

4658, 4751

RsrII

CGGWCCG

2116

SacII

CCGCGG

2006

SmaI

CCCGGG

2420

SspI

AATATT

1024, 1185, 2747

XbaI

TCTAGA

1483

XmaI

CCCGGG

2418

XmnI

GAANNNNTTC

2952

Acc65I

GGTACC

no cuts

AgeI

ACCGGT

no cuts

AsiSI

GCGATCGC

no cuts

AvrII

CCTAGG

no cuts

BamHI

GGATCC

no cuts

BbsI

GAAGAC

no cuts

BglII

AGATCT

no cuts

BsaI

GGTCTC

no cuts

BsiWI

CGTACG

no cuts

BsmBI

CGTCTC

no cuts

BstBI

TTCGAA

no cuts

ClaI

ATCGAT

no cuts

EagI

CGGCCG

no cuts

FseI

GGCCGGCC

no cuts

AAGCTT

no cuts

HindIII
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Name

Sequence

5' Cut Positions

KpnI

GGTACC

no cuts

MfeI

CAATTG

no cuts

NdeI

CATATG

no cuts

NheI

GCTAGC

no cuts

NotI

GCGGCCGC

no cuts

PacI

TTAATTAA

no cuts

PmeI

GTTTAAAC

no cuts

PpuMI

RGGWCCY

no cuts

PspXI

VCTCGAGB

no cuts

PstI

CTGCAG

no cuts

SacI

GAGCTC

no cuts

SalI

GTCGAC

no cuts

SanDI

GGGWCCC

no cuts

SapI
SbfI
SfiI

GCTCTTC
CCTGCAGG
GGCCNNNNNGGCC

no cuts
no cuts
no cuts

SnaBI

TACGTA

no cuts

SpeI

ACTAGT

no cuts

SphI

GCATGC

no cuts

SwaI

ATTTAAAT

no cuts

XhoI

CTCGAG

Sequence
1 CCCGTAGAAA AGATCAAAGG ATCTTCTTGA GATCCTTTTT TTCTGCGCGT AATCTGCTGC
61 TTGCAAACAA AAAAACCACC GCTACCAGCG GTGGTTTGTT TGCCGGATCA AGAGCTACCA
121 ACTCTTTTTC CGAAGGTAAC TGGCTTCAGC AGAGCGCAGA TACCAAATAC TGTTCTTCTA
181 GTGTAGCCGT AGTTAGCCCA CCACTTCAAG AACTCTGTAG CACCGCCTAC ATACCTCGCT
241 CTGCTAATCC TGTTACCAGT GGCTGCTGCC AGTGGCGATA AGTCGTGTCT TACCGGGTTG
301 GACTCAAGAC GATAGTTACC GGATAAGGCG CAGCGGTCGG GCTGAACGGG GGGTTCGTGC
361 ACACAGCCCA GCTTGGAGCG AACGACCTAC ACCGAACTGA GATACCTACA GCGTGAGCTA
421 TGAGAAAGCG CCACGCTTCC CGAAGGGAGA AAGGCGGACA GGTATCCGGT AAGCGGCAGG
481 GTCGGAACAG GAGAGCGCAC GAGGGAGCTT CCAGGGGGAA ACGCCTGGTA TCTTTATAGT
541 CCTGTCGGGT TTCGCCACCT CTGACTTGAG CGTCGATTTT TGTGATGCTC GTCAGGGGGG
601 CGGAGCCTAT GGAAAAACGC CAGCAACGCG GCCTTTTTAC GGTTCCTGGC CTTTTGCTGG
661 CCTTTTGCTC ACATGTTCTT TCCTGCGTTA TCCCCTGATT CTGTGGATAA CCGTATTACC
721 GCCTTTGAGT GAGCTGATAC CGCTCGCCGC AGCCGAACGA CCGAGCGCAG CGAGTCAGTG
781 AGCGAGGAAG CGGAAGGCGA GAGTAGGGAA CTGCCAGGCA TCAAACTAAG CAGAAGGCCC
841 CTGACGGATG GCCTTTTTGC GTTTCTACAA ACTCTTTCTG TGTTGTAAAA CGACGGCCAG
901 TCTTAAGCTC GGGCCCCCTG GGCGGTTCTG ATAACGAGTA ATCGTTAATC CGCAAATAAC
961 GTAAAAACCC GCTTCGGCGG GTTTTTTTAT GGGGGGAGTT TAGGGAAAGA GCATTTGTCA
1021 GAATATTTAA GGGCGCCTGT CACTTTGCTT GATATATGAG AATTATTTAA CCTTATAAAT

no cuts

42
1081 GAGAAAAAAG CAACGCACTT TAAATAAGAT ACGTTGCTTT TTCGATTGAT GAACACCTAT
1141 AATTAAACTA TTCATCTATT ATTTATGATT TTTTGTATAT ACAATATTTC TAGTTTGTTA
1201 AAGAGAATTA AGAAAATAAA TCTCGAAAAT AATAAAGGGA AAATCAGTTT TTGATATCAA
1261 AATTATACAT GTCAACGATA ATACAAAATA TAATACAAAC TATAAGATGT TATCAGTATT
1321 TATTATCATT TAGAATAAAT TTTGTGTCGC CCTTAATTGT GAGCGGATAA CAATTACGAG
1381 CTTCATGCAC AGTGAAATCA TGAAAAATTT ATTTGCTTTG TGAGCGGATA ACAATTATAA
1441 TATGTGGAAT TGTGAGCGCT CACAATTCCA CAACGGTTTC CCTCTAGAAA TAATTTTGTT
1501 TAACTTTTAA GGAGGTAAAA AATGCATCAT CATCATCACC ACATGGCCAG CAAGGGCGAA
1561 GAACTGTTTA CGGGCGTCGT TCCGATCCTG GTTGAGCTGG ATGGTGATGT GAACGGCCAC
1621 AAGTTCAGCG TTTCCGGTGA GGGTGAGGGC GATGCTACCT ATGGTAAACT GACGCTGAAA
1681 TTCATTTGCA CGACTGGTAA GCTGCCGGTC CCATGGCCGA CCCTGGTCAC GACCTTTTCC
1741 TATGGTGTTC AGTGTTTCAG CCGTTATCCG GATCACATGA AACAACATGA CTTCTTTAAG
1801 AGCGCGATGC CTGAGGGTTA CGTGCAAGAG CGCACTATTA GCTTCAAAGA TGACGGTAAC
1861 TACAAAACCC GTGCAGAAGT CAAGTTTGAG GGCGACACCT TGGTGAATCG CATCGAGCTG
1921 AAGGGCATTG ACTTCAAGGA AGATGGCAAC ATCCTGGGTC ATAAACTGGA GTACAACTAC
1981 AATTCTCATA ACGTTTACAT TACCGCGGAT AAACAGAAAA ATGGCATTAA GGCCAACTTT
2041 AAGATTCGTC ACAACATCGA AGATGGCTCG GTGCAGTTGG CAGACCACTA TCAACAAAAT
2101 ACCCCGATCG GTGACGGTCC GGTTCTGCTG CCGGATAATC ACTACCTGAG CACGCAAAGC
2161 GCGCTGAGCA AAGACCCGAA TGAAAAGCGT GACCACATGG TCCTGTTGGA ATTCGTGACC
2221 GCTGCGGGTA TCACCCACGG TATGGACGAA CTGTACAAAG AAAACCTGTA TTTTCAGGGT
2281 GACGTGTCTA CCAGCCAGGC AGTTCTGCCG GATGACTTCC CGCGCTACCC GGTGGGCAAA
2341 GCGTTTAAGT TCGACACGTG GCGTCAGAGC GCGGGTCGTC TGTAAGGTTG ACCCCAAGGG
2401 CGACACCCCA TAATTAGCCC GGGCGAAAGG CCCAGTCTTT CGACTGAGCC TTTCGTTTTA
2461 TTTGATGCCT GGCAGTTCCC TACTCTCGCA TGGGGAGTCC CCACACTACC ATCGGCGCTA
2521 CGGCGTTTCA CTTCTGAGTT CGGCATGGGG TCAGGTGGGA CCACCGCGCT ACTGCCGCCA
2581 GGCAAACAAG GGGTGTTATG AGCCATATTC AGGTATAAAT GGGCTCGCGA TAATGTTCAG
2641 AATTGGTTAA TTGGTTGTAA CACTGACCCC TATTTGTTTA TTTTTCTAAA TACATTCAAA
2701 TATGTATCCG CTCATGAGAC AATAACCCTG ATAAATGCTT CAATAATATT GAAAAAGGAA
2761 GAATATGAGT ATTCAACATT TCCGTGTCGC CCTTATTCCC TTTTTTGCGG CATTTTGCCT
2821 TCCTGTTTTT GCTCACCCAG AAACGCTGGT GAAAGTAAAA GATGCTGAAG ATCAGTTGGG
2881 TGCACGAGTG GGTTACATCG AACTGGATCT CAACAGCGGT AAGATCCTTG AGAGTTTTCG
2941 CCCCGAAGAA CGTTTTCCAA TGATGAGCAC TTTTAAAGTT CTGCTATGTG GCGCGGTATT
3001 ATCCCGTATT GACGCCGGGC AAGAGCAACT CGGTCGCCGC ATACACTATT CTCAGAATGA
3061 CTTGGTTGAG TACTCACCAG TCACAGAAAA GCATCTTACG GATGGCATGA CAGTAAGAGA
3121 ATTATGCAGT GCTGCCATAA CCATGAGTGA TAACACTGCG GCCAACTTAC TTCTGACAAC
3181 GATCGGAGGA CCGAAGGAGC TAACCGCTTT TTTGCACAAC ATGGGGGATC ATGTAACTCG
3241 CCTTGATCGT TGGGAACCGG AGCTGAATGA AGCCATACCA AACGACGAGC GTGACACCAC
3301 GATGCCTGTA GCGATGGCAA CAACGTTGCG CAAACTATTA ACTGGCGAAC TACTTACTCT
3361 AGCTTCCCGG CAACAATTAA TAGACTGGAT GGAGGCGGAT AAAGTTGCAG GACCACTTCT
3421 GCGCTCGGCC CTTCCGGCTG GCTGGTTTAT TGCTGATAAA TCCGGAGCCG GTGAGCGTGG
3481 TTCTCGCGGT ATCATCGCAG CGCTGGGGCC AGATGGTAAG CCCTCCCGTA TCGTAGTTAT
3541 CTACACGACG GGGAGTCAGG CAACTATGGA TGAACGAAAT AGACAGATCG CTGAGATAGG
3601 TGCCTCACTG ATTAAGCATT GGTAAGCGGC GCGCCATCGA ATGGCGCAAA ACCTTTCGCG

43
3661 GTATGGCATG ATAGCGCCCG GAAGAGAGTC AATTCAGGGT GGTGAATATG AAACCAGTAA
3721 CGTTATACGA TGTCGCAGAG TATGCCGGTG TCTCTTATCA GACCGTTTCC CGCGTGGTGA
3781 ACCAGGCCAG CCACGTTTCT GCGAAAACGC GGGAAAAAGT GGAAGCGGCG ATGGCGGAGC
3841 TGAATTACAT TCCCAACCGC GTGGCACAAC AACTGGCGGG CAAACAGTCG TTGCTGATTG
3901 GCGTTGCCAC CTCCAGTCTG GCCCTGCACG CGCCGTCGCA AATTGTCGCG GCGATTAAAT
3961 CTCGCGCCGA TCAACTGGGT GCCAGCGTGG TGGTGTCGAT GGTAGAACGA AGCGGCGTCG
4021 AAGCCTGTAA AGCGGCGGTG CACAATCTTC TCGCGCAACG CGTCAGTGGG CTGATCATTA
4081 ACTATCCGCT GGATGACCAG GATGCCATTG CTGTGGAAGC TGCCTGCACT AATGTTCCGG
4141 CGTTATTTCT TGATGTCTCT GACCAGACAC CCATCAACAG TATTATTTTC TCCCATGAGG
4201 ACGGTACGCG ACTGGGCGTG GAGCATCTGG TCGCATTGGG TCACCAGCAA ATCGCGCTGT
4261 TAGCGGGCCC ATTAAGTTCT GTCTCGGCGC GTCTGCGTCT GGCTGGCTGG CATAAATATC
4321 TCACTCGCAA TCAAATTCAG CCGATAGCGG AACGGGAAGG CGACTGGAGT GCCATGTCCG
4381 GTTTTCAACA AACCATGCAA ATGCTGAATG AGGGCATCGT TCCCACTGCG ATGCTGGTTG
4441 CCAACGATCA GATGGCGCTG GGCGCAATGC GCGCCATTAC CGAGTCCGGG CTGCGCGTTG
4501 GTGCGGATAT CTCGGTAGTG GGATACGACG ATACCGAAGA TAGCTCATGT TATATCCCGC
4561 CGTTAACCAC CATCAAACAG GATTTTCGCC TGCTGGGGCA AACCAGCGTG GACCGCTTGC
4621 TGCAACTCTC TCAGGGCCAG GCGGTGAAGG GCAATCAGCT GTTGCCAGTC TCACTGGTGA
4681 AAAGAAAAAC CACCCTGGCG CCCAATACGC AAACCGCCTC TCCCCGCGCG TTGGCCGATT
4741 CATTAATGCA GCTGGCACGA CAGGTTTCCC GACTGGAAAG CGGGCAGTGA CTCATGACCA
4801 AAATCCCTTA ACGTGAGTTA CGCGCGCGTC GTTCCACTGA GCGTCAGAC
Only the synthesized DNA fragment (in red) has been sequence verified. We do not
guarantee the vector sequence.

